Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia (ERUDITE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia, Followed by Open-Label Treatment
Sponsor: Neurocrine Biosciences
Terminated
Failed to meet the primary endpoint
Other terminated trials from Neurocrine Biosciences
This PHASE2 trial investigates Schizophrenia and is currently terminated or withdrawn. Neurocrine Biosciences leads this study, which shows 15 recorded versions since 2021 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Terminated PHASE2
-
Jan 2025 — Aug 2025 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 10 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2023 — May 2024 [monthly]
Recruiting PHASE2
-
Feb 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Jul 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE2
First recorded
Dec 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Neurocrine Biosciences
For direct contact, visit the study record on ClinicalTrials.gov .